Literature DB >> 23672909

Treatment of osteoid osteoma with CT-guided percutaneous radiofrequency thermoablation.

Luigi de Palma1, Roberto Candelari, Ettore Antico, Rocco Politano, Eugenio Luniew, Maurizio Giordanengo, Silvio Di Giansante, Mario Marinelli, Enrico Paci.   

Abstract

Osteoid osteoma is a benign bone tumor with a male predominance occurring mainly in children and young adults. The most common symptom is intermittent pain that worsens at night and is at least partially relieved by nonsteroidal anti-inflammatory drugs. The purpose of this study was to assess the long-term effectiveness of computed tomography-guided percutaneous radiofrequency thermoablation in patients with a minimum follow-up of 2 years. Twenty patients with osteoid osteoma (15 men and 5 women) with a mean age of 20.7 years (range, 4-61 years; 12 patients aged 20 years or younger) underwent computed tomography-guided percutaneous radiofrequency thermoablation. Lesion sites were the femur (n=9), tibia (n=7), pelvis (n=1), talus (n=1), cuneiform bone (n=1), and humerus (n=1). Mean follow-up was 44 months (range, 3-106 months). Pain relief was significant in 95% of patients; it disappeared within 24 hours in 14 patients, within 3 days in 4, and within 7 days in 1. The patient with persistent symptoms underwent another percutaneous radiofrequency thermoablation procedure that was successful. The difference between pre- and postoperative pain was significant (P ≤ .01). No recurrences occurred. Computed tomography-guided percutaneous radiofrequency thermoablation is a safe, minimally invasive, and economical procedure with high technical and clinical success rates, and it effectively and durably enhances quality of life. Copyright 2013, SLACK Incorporated.

Entities:  

Mesh:

Year:  2013        PMID: 23672909     DOI: 10.3928/01477447-20130426-19

Source DB:  PubMed          Journal:  Orthopedics        ISSN: 0147-7447            Impact factor:   1.390


  8 in total

1.  Radiofrequency ablation under 3D intraoperative Iso-C C-arm navigation for the treatment of osteoid osteomas.

Authors:  Feng Yu; Xiao-Hui Niu; Qing Zhang; Hai-Tao Zhao; Li-Hui Xu; Zhi-Ping Deng
Journal:  Br J Radiol       Date:  2015-09-29       Impact factor: 3.039

2.  Radiofrequency ablation of osteoid osteoma in the atlas: A case report.

Authors:  Jun Yang; Wei Li; Yu Yin; Zhi Li; Caifang Ni
Journal:  Interv Neuroradiol       Date:  2017-11-20       Impact factor: 1.610

3.  CT-guided radiofrequency ablation for osteoid osteomas: a systematic review.

Authors:  Mickael Tordjman; Laetitia Perronne; Guillaume Madelin; Rahul D Mali; Christopher Burke
Journal:  Eur Radiol       Date:  2020-06-09       Impact factor: 5.315

4.  COMPARISON OF RADIOFREQUENCY ABLATION AND CURETTAGE IN OSTEOID OSTEOMA IN CHILDREN.

Authors:  Ferdi Göksel; Ayşe Aycan; Cenk Ermutlu; Umut Hatay Gölge; Bartu Sarısözen
Journal:  Acta Ortop Bras       Date:  2019 Mar-Apr       Impact factor: 0.513

5.  Osteoid osteoma of the lunatum mimicking Kienböck's disease.

Authors:  Mehmet Derviş Güner; Haldun Onuralp Kamburoğlu; Umut Bektaş; Şadan Ay
Journal:  Case Reports Plast Surg Hand Surg       Date:  2015-01-06

6.  Effectiveness of Computed Tomography Guided Percutaneous Radiofrequency Ablation Therapy for Osteoid Osteoma: Initial Results and Review of the Literature.

Authors:  Erdal Karagöz; Deniz Özel; Fuat Özkan; Betül Duran Özel; Özgur Özer; Zafer Ünsal Coşkun
Journal:  Pol J Radiol       Date:  2016-06-22

Review 7.  Osteoid osteoma: which is the best mininvasive treatment option?

Authors:  Anna Parmeggiani; Claudia Martella; Luca Ceccarelli; Marco Miceli; Paolo Spinnato; Giancarlo Facchini
Journal:  Eur J Orthop Surg Traumatol       Date:  2021-04-11

8.  Cone beam computed tomography (CBCT) guidance is helpful in reducing dose exposure to pediatric patients undergoing radiofrequency ablation of osteoid osteoma.

Authors:  Francesco Fiore; Francesco Somma; Roberto D'Angelo; Luca Tarotto; Vincenzo Stoia
Journal:  Radiol Med       Date:  2021-12-27       Impact factor: 3.469

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.